Actos on a good-news roll

The EU's drug committee also gave the go-ahead for a new combo pill that melds the diabetes remedy Actos with old blood-sugar standby metformin. This thumbs-up follows a spate of good news for Actos, including a new study unveiled Wednesday that showed it controlled blood sugar and lipid levels better than Avandia did. Another study, presented at the same meeting of the European Association for the Study of Diabetes, showed that Actos cut heart attack risk by 38 percent.

- check out this EMEA release on the Actos combo drug
- and this release on the Actos studies

Related Articles:
Actos study points to reduction in heart attacks, strokes. Report
Diabetes drug helps reduce rate of strokes. Report
Avandia risks back in the headlines. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.